1. Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms
- Author
-
Yanyan Cheng, Nanping Wang, Lei Xiao, and Xin Nie
- Subjects
Pharmacology ,Carotid Intima-Media Thickness ,Antioxidants ,Vascular Stiffness ,Cell Movement ,Diabetes mellitus ,medicine ,Animals ,Humans ,Hypoglycemic Agents ,Pharmacology (medical) ,Myocardial infarction ,Renal Insufficiency, Chronic ,Sodium-Glucose Transporter 2 Inhibitors ,Stroke ,Cell Proliferation ,Randomized Controlled Trials as Topic ,business.industry ,Hemodynamics ,Endothelial Cells ,Type 2 Diabetes Mellitus ,General Medicine ,Atherosclerosis ,medicine.disease ,Renal glucose reabsorption ,Cardiovascular Diseases ,Heart failure ,Sodium/Glucose Cotransporter 2 ,Inflammation Mediators ,Cardiology and Cardiovascular Medicine ,business ,Kidney disease - Abstract
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are new antidiabetic drugs that reduce hyperglycemia by inhibiting the glucose reabsorption in renal proximal tubules. Clinical studies have shown that SGLT2 inhibitors not only improve glycemic control but also reduce major adverse cardiovascular events (MACE, cardiovascular and total mortality, fatal or nonfatal myocardial infarction or stroke) and hospitalization for heart failure (HF), and improve outcome in chronic kidney disease. These cardiovascular and renal benefits have now been confirmed in both diabetes and non-diabetes patients. The precise mechanism(s) responsible for the protective effects are under intensive investigation. This review examines current evidence on the cardiovascular benefits of SGLT2 inhibitors, with a special emphasis on the vascular actions and their potential mechanisms.
- Published
- 2021